<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165944</url>
  </required_header>
  <id_info>
    <org_study_id>08-1343</org_study_id>
    <nct_id>NCT01165944</nct_id>
  </id_info>
  <brief_title>Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus</brief_title>
  <official_title>Effectiveness of Pramlintide on Control of Post-Transplant Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-transplant diabetes mellitus (PTDM) develops in up to 30% of patients undergoing solid
      organ transplantation. This disease is difficult to treat as the levels of glycemia fluctuate
      in response to variations in doses of steroid and other immunosuppressive agents. At the same
      time, poorly controlled hyperglycemia affects negatively graft function and survival as well
      as on the ability of the immunocompromised host to fight infections. The investigators
      hypothesize that the addition of Pramlintide (Symlin) to the management of patients with PTDM
      would help patients with post-transplant diabetes attain better control at the critical time
      of titration of immunosuppressive regimens. The primary objective of this proposal is to
      improve glycemic control of diabetes with Pramlintide in patients with post-transplant
      diabetes at 3 and 6 months of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HgA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Primary outcomes utilized in this study will be endpoints of HbA1C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous glucose monitoring</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary outcomes will include mean blood glucose levels assessed by continuous glucose monitoring (CGM) at 1, 3, and 6 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Standard diabetes therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard diabetes therapy with either oral agents or insulin injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral diabetic agents and pramlintide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin injection with pramlintide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramlintide</intervention_name>
    <description>Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks</description>
    <arm_group_label>Oral diabetic agents and pramlintide</arm_group_label>
    <arm_group_label>Insulin injection with pramlintide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-transplant diabetes (PTMD)

          -  Aged 20-70

          -  Diagnosis of diabetes within the last 6-18 months

          -  Stable medications

          -  Stable weight for 3 months

          -  Serum creatinine &lt; 1.5 mg/dL

        Exclusion Criteria:

          -  Pre-transplant diabetes

          -  Major postoperative complications following transplant

          -  Pregnancy

          -  Significant GI discomfort with nausea or vomiting

          -  Inability to learn continuous glucose monitoring

          -  Development of diabetes more than 4 years after transplant

          -  omen of child-bearing potential who use birth control pills and have fasting
             triglycerides of &gt; 400 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Draznin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post transplant diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

